METPAG-E
METPAG-E is a fixed-dose combination of Metformin and Empagliflozin for the management of Type 2 Diabetes Mellitus. Provides enhanced glycaemic control while offering cardiovascular and renal protective benefits beyond glucose lowering alone.
Dual Antidiabetic — Biguanide + SGLT2 Inhibitor
Metformin reduces hepatic glucose production and improves insulin sensitivity. Empagliflozin inhibits SGLT2 to promote urinary glucose excretion. Together they provide complementary glycaemic control with proven heart and kidney benefits.
science Molecular Profile
inventory_2 Packaging
public Distribution Reach
Cleared for logistics within:
Thermal Integrity
"Our cold-chain protocol ensures zero-fluctuation transport from laboratory to clinician."
Cold-Chain Requirements
Real-time Monitoring
Integrated Bluetooth temperature loggers in every shipping container provide minute-by-minute data.
Passive VIP Insulation
Vacuum Insulated Panels (VIP) maintain critical temperature stability for up to 144 hours.
Interested in METPAG-E?
Submit an inquiry and our team will get back to you with availability and pricing.
Distribution Inquiry
